ReviewActa parasitologica2026
Phytoextracts Used in the Treatment of Cryptosporidiosis and Giardiasis: Current State.
Review in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phytoextracts are safer, more affordable, and more readily available than conventional medications, making them promising anti-parasitic treatment options. Cryptosporidium species (spp.) and Giardia duodenalis are protozoan parasites responsible for cryptosporidiosis and giardiasis, respectively, primarily affecting immunocompromised individuals, children, and populations in developing countries. Although treatment options exist, many of them have significant side effects. The current review aims to evaluate the efficacy of phytoextracts tested against Cryptosporidium spp. and G. duodenalis infections. The current review indicated that the Asteraceae and Rutaceae families were the most extensively investigated sources of phytoextracts. Additionally, Zingiber officinale is the only extract to demonstrate efficacy against both parasites in in vivo studies. Furthermore, Curcuma longa and Morinda royoc showed the highest in vitro efficacy against Cryptosporidium spp. and G. duodenalis, respectively. These results underscore the potential of phytoextracts as alternative therapeutic modalities for the treatment of cryptosporidiosis and giardiasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.